27455 Au / 295897 16/6 /2011 (final ucision taken to 010635)



Australian Government

Department of Health and Ageing Therapeutic Goods Administration

Draft Compositional Guideline for XXXX

Name of the ingredient

XXXX (AAN) (check the ARTG permitted ingredients list for the correct name and type of substance)

Definition of the ingredient

The substance should be defined as to its origin (for example: genus, species, part of the organism, geographical location of harvest, time of harvest) and method of manufacture (for example: cultivated or wild, extracted, dried, distilled purified by ion-exchange chromatography). This must be the same as the process against which the safety/toxicology data was evaluated by the TGA.

Molecular formula (*if applicable*):

CAS Number (*if applicable*):

Table 1.Ingredient specific requirements

Test	Method reference	Acceptance criteria
Description		
This should include all physical properties, such as appearance, colour, odour, taste.	Where there is no formal testing regime required e.g. appearance or odour, a description such as 'visual' or 'organoleptic' is satisfactory.	Complies

Test	Method reference	Acceptance criteria
Characteristics Properties of the substance that ensure its quality. Pharmacopoeial tests and limits for comparable substances should be considered when determining what to include. Some examples include: Loss on drying Residue on ignition* Sulfated ash* Solubility Melting Point pH of solution.	List pharmacopoeial methods (attach details of proprietary methods).	Amounts should be declared as a percentage, for example: <1.0 % w/w. Ranges should be stated rather than single values. Consideration should be given to the number of significant figures, for example: pH 3.5–4.5 is preferable to pH 4, in line with pharmacopoeial practice.
Identification The identification test(s) <u>must</u> be able to unambiguously distinguish the substance from any other substance, and may include 'fingerprint' tests such as TLC, HPLC or IR which must be compared to an authenticated reference material. More than one test may be appropriate. For pure substances, chromatographic retention time alone is generally considered inadequate as a method of identification.	List methods of identification. Refer to pharmacopoeial methods where possible (attach details of proprietary methods).	Complies, for example: matches spectrum of authenticated reference material.
Assay Describe tests that determine the presence and quantity of a specific substance. In case of herbal materials, preparations, or other complex mixtures (for example: herbal extracts), appropriate marker compounds may be assayed.	State and if necessary describe methods of assay or provide brief details.	Limits for assay(s) taking into account practical but reasonable biological, physical and chemical variation.
Notes		

* The test is appropriate when performed on inorganic material. For organic substances, the test should be included under "Other organic or inorganic impurities or toxins".

Table 2.Incidental constituents

Where justified, certain tests for incidental constituents may be excluded based on the origin and processing of the substance, for example: a dried leaf, otherwise unprocessed, may be exempted from residual solvent testing. Other incidentals, such as scheduled contaminants (for example: bromides, ephedrine) or radioactivity should be included where appropriate.

Test	Method reference	Acceptance criteria
Solvent residues		
Specifically address solvents that may be present.	List methods of assay, for example: BP 2011 (Appendix VIII L. Residual solvents: Ph	Limits of total solvents
Address any additional solvents that may be used in the production, preparation, manufacturing or formulation.	Eur method 2.4.24).	Solvent specific limits
Incidental metals and non-metals		
Specifically address the metals in the current BP or other default standard (Ph Eur, USP) limit tests for heavy metals.	List methods of assay, for example: BP 2011 (Appendix VII): Ph Fur	Limits of total heavy metals
Include any limits for specific metals or non-metals, for example: lead, cadmium, mercury, arsenic, cyanide.	method 2.4.8 or in-house.	Metal specific limits
Pesticide residues and environmental contaminants: (including agricultural and veterinary substances)	. , ,	
Specifically address the limits stipulated in the current BP (or Ph Eur, USP), and whether the product would comply with these limits. In addition, state any additional residue limits that may be relevant.	List methods of assay, for example: BP 2011(Appendix XI L, Pesticide residues; Ph Eur method 2.8.13).	Complies

)

Test		Method reference	Acceptance criteria
Other organic or in impurities or toxin	organic s		
Include other substan safety risk, or may be significance.	nces that may pose a e of therapeutic		<i>Limit of impurities in substance</i>
What specific substance are assayed, for example : dioxins, PCBs, mycotoxins. Give consideration to related substances such as by-products, co-extracted substances, inactive isomers and degradation products.		List methods of assay, refer to pharmacopoeial methods where possible, for example: BP, Ph Eur, USP.	Impurity specific limits
Ash Residue on Ignition Sulfated ash			Amounts should be declared as a percentage, for example: <1.0 % w/w.
Peroxide value			
Microbiology	While substance manufacturers are encouraged to include limits for objectionable microorganisms, it is the product into which those substances are formulated that is subject to a legally binding set of criteria. The Therapeutic Goods Order No. 77 <i>'Microbiological Standards for Medicines'</i> mandates that any finished product which contains the ingredient, alone or in combination with other ingredients, must comply with the microbial acceptance criteria set by Clause 9 of the Order.		
Notes			

Key to abbreviations: - insert or delete as required

- BP = British Pharmacopoeia
- HPLC = High-pressure liquid chromatography
- IR = Infrared spectrophotometry
- Ph Eur = European Pharmacopoeia
- TLC = Thin layer chromatography
- USP = United States Pharmacopoeia